DMAC

DiaMedica Therapeutics Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website diamedica.com
Employees(FY) 16
ISIN CA25253X2077

Performance

-6.96%

+8.9%

+33.37%

+61.08%

+7.09%

YTD

+106.21%

Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Advanced Technical Analysis

Technical Analysis of DMAC 2025-01-31

The stock exhibits a bullish sentiment with a Moving Average Score of 70, indicating strong upward momentum, while the Oscillators Score of 36 suggests some bearish pressure. Overall, the Technical Score of 55 reflects a neutral stance, implying that while there is potential for growth, caution is warranted due to mixed signals from the oscillat...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DMAC

Stock Rank

Recent News & Updates

2024-12-02 19:25
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia(Businesswire)
2024-11-14 13:06
Q3 2024 DiaMedica Therapeutics Inc Earnings Call(Yahoo Finance)
2024-11-13 03:20
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results(Businesswire)
2024-11-13 03:05
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia(Businesswire)
2024-11-11 19:23
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference(Businesswire)
2024-11-05 19:32
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024(Businesswire)
2024-10-09 17:28
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial(Yahoo Finance)
2024-10-08 20:27
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia(Businesswire)
2024-09-04 04:15
DiaMedica Therapeutics Upcoming Conference Participation(Businesswire)
2024-08-07 04:15
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results(Businesswire)
2024-07-31 21:40
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?(Yahoo Finance)
2024-07-31 20:20
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024(Businesswire)
2024-07-10 20:00
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia(Businesswire)
2024-06-30 20:00
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement(Businesswire)
2024-06-25 20:15
DiaMedica Therapeutics Announces $11.8 Million Private Placement(Businesswire)
2024-06-25 20:00
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia(Businesswire)
2024-05-13 00:08
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-08 10:54
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-08 04:30
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results(Businesswire)
2024-05-01 20:55
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024(Businesswire)
2024-04-17 22:06
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch(Zacks)
2024-04-17 04:08
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke(Businesswire)
2024-04-14 21:35
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner(Zacks)
2024-03-24 22:00
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript(Yahoo Finance)
2024-03-24 22:00
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-22 18:00
Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich(Yahoo Finance)
2024-03-19 09:53
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023(Investorplace)
2024-03-19 04:15
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results(Businesswire)
2024-01-29 03:13
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference(Businesswire)
2024-01-21 19:23
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer(Businesswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.